Tarlatamab (Imdelltra)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses tarlatamab 1 mg or 10 mg, initial dose of 1 mg on day 1 followed by 10 mg on day 8 and day 15 and q.2.w. thereafter, IV infusion. Indication: For the treatment of adult patients with ES-SCLC with disease progression on or after at least 2 prior lines of therapy including platinum-based chemotherapy